Navigating Brazil’s Regulatory Landscape: Achieving Compliance with DDReg Pharma

-


Promotional graphic for DDReg Pharma showcasing PV and RA services in Brazil, featuring the Brazilian flag, a professional man in a suit holding a clipboard, service categories including Health & Pharmaceuticals, Biopharma, Cosmetics, Medical Devices, and Food & Nutrition in colored boxes with icons, and regulatory agency logos at the bottom alongside the DDReg logo.


The Brazilian pharmaceutical market is one of the most dynamic and stringently regulated in Latin America.   For global life sciences companies, entering this territory offers immense opportunity, but it also requires a deep understanding of the Agência Nacional de Vigilância Sanitária (ANVISA).   At DDReg Pharma, we bridge the gap between global innovation and local compliance, providing specialized Regulatory Affairs and Pharmacovigilance (PV) services tailored to the Brazilian market.



The ANVISA Challenge: Beyond Just Paperwork

ANVISA is known for its rigorous standards, often harmonizing with international bodies like ICH and WHO, yet maintaining unique local requirements. Successfully launching a product in Brazil isn't just about submitting a dossier; it’s about strategic alignment.

From ensuring Good Manufacturing Practice (GMP) certification to managing the complexity of eCTD/CTD submissions, the hurdles are significant. This is where DDReg Pharma excels. Our team acts as your strategic partner, offering end-to-end Regulatory Affairs support in Brazil including gap analysis, dossier preparation, and direct liaison with ANVISA—to accelerate your time-to-market.



Strengthening Patient Safety: PV Services in Brazil

Once a product is on the market, the focus shifts to robust monitoring. Under Resolution RDC No. 406/2020, Brazil has strict guidelines for Good Pharmacovigilance Practices (GVP).

DDReg Pharma provides a comprehensive PV framework to safeguard your products and patients, including:

  • Local QPPV/LQPPV Representation: Appointing a dedicated local qualified person as required by law.

  • VigiMed Reporting: Expert management of Individual Case Safety Reports (ICSR) via Brazil’s official platform.

  • Localized Risk Management Plans (RMPs): Tailoring global safety strategies to meet specific Brazilian population needs and regulatory expectations.

  • PSMF Maintenance: Establishing and updating the Brazil-specific Pharmacovigilance System Master File.

Why DDReg Pharma?

With over 16 years of experience and a presence in over 50 countries, DDReg Pharma combines global quality standards with local operational excellence. Whether you are navigating a new product registration or seeking a reliable partner for post-market surveillance, our AI-driven regulatory intelligence and expert-led teams ensure your compliance is never in question.

Partner with DDReg Pharma today and turn regulatory complexity into a competitive advantage in Brazil.

Connect With Us

Stay updated on the latest regulatory insights and industry news by following DDReg Pharma on our social media platforms:

Location: Brazil

Comments

Post a Comment

Popular posts from this blog

What is an IMPD? Understanding Its Role in Clinical Trials and Drug Development

-
Image
What is an IMPD? Understanding Its Role in Clinical Trials and Drug Development An Investigational Medicinal Product Dossier (IMPD) is a key document in the clinical trial and drug development process, specifically for drugs or biologics undergoing testing in human clinical trials within the European Union (EU). It serves as a comprehensive report detailing the quality, manufacture, and control of the investigational product. The IMPD is a crucial regulatory submission required by the European Medicines Agency (EMA) or national regulatory bodies to evaluate whether a clinical trial can proceed. Key Components of an IMPD The IMPD includes several sections, providing information that ensures the safety and efficacy of the investigational product. These sections typically cover: Product Description and Composition: The IMPD provides detailed information about the investigational product, including its chemical composition, formulation, and dosage forms. Manufacturing and Control: This...
Read more

GMP Compliance in the Era of Advanced Therapies and Biologics

-
Image
Navigating the New Frontier: GMP Compliance for ATMPs and Biologics The global biopharmaceutical industry is undergoing a transformative shift as Advanced Therapy Medicinal Products (ATMPs)—including gene therapies, somatic cell therapies, and tissue-engineered products—and complex biologics become central to innovation pipelines. With over 1,900 active CGT clinical trials globally as of Q2 2025, according to a report by ARM, these living therapies offer unprecedented clinical benefits. However, their unique nature presents a significant challenge: traditional Good Manufacturing Practice (GMP) frameworks, designed for stable, small molecule drugs, are often not directly applicable. Their development, manufacturing, and distribution demand a fundamentally different approach to compliance. often requiring specialized GMP compliance services . The GMP Paradigm Shift for Living Products What makes ATMPs and biologics so unique from a GMP perspective? Living Products with Inherent Variabili...
Read more

Quasi Drugs: Regulatory & Commercial Considerations for Japan and South Korea

-
Image
Navigating Quasi-Drug Regulations and Market Entry in Japan and South Korea In the dynamic Asia-Pacific market, quasi drugs represent a unique regulatory category that bridges the gap between cosmetics and pharmaceuticals . Particularly in Japan and South Korea, quasi drugs have gained traction for their hybrid benefits offering therapeutic claims while maintaining a relatively simpler regulatory pathway compared to full-fledged drugs.    Understanding the regulatory and commercial landscape of quasi drugs in these two key markets is essential for global companies aiming to enter or expand in East Asia. This article explores the updated guidelines, approval requirements, and commercialization opportunities for quasi drugs in Japan and South Korea.  What Are Quasi Drugs? Quasi drugs are defined as products that have mild pharmacological effects or physiological functions. They may not be as potent as traditional drugs, but they go beyond the scope of general cosmetics. Th...
Read more